Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury
Spinal Cord Injury
About this trial
This is an interventional treatment trial for Spinal Cord Injury focused on measuring spinal cord injury (SCI)
Eligibility Criteria
Inclusion Criteria:
- Aged 18-75 years inclusive;
- Diagnosis of acute SCI;
- Injury is less than 24 hours old;
- ISNCSCI Impairment Scale Grade "A," "B" or "C" based upon first ISNCSCI evaluation after arrival to the hospital;
- Neurological level of injury between C4-C8 based upon first ISNCSCI evaluation after arrival to the hospital;
- Women of childbearing potential must have a negative serum β-hCG pregnancy test or a negative urine pregnancy test;
- Patient is willing to participate in the study;
- Informed consent document signed by patient or witnessed informed consent document;
- No contraindications for study treatment(s);
- Able to cooperate in the completion of a standardized neurological examination by ISNCSCI standards (includes patients who are on a ventilator).
Exclusion Criteria:
- Injury arising from penetrating mechanism;
- Significant concomitant head injury defined by a Glasgow Coma Scale (GCS) score < 14 with a clinically significant abnormality on a head CT (head CT required only for patients suspected to have a brain injury at the discretion of the investigator);
- Pre-existing neurologic or mental disorder which would preclude accurate evaluation and follow-up (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric disorder with- hallucinations and/or delusions or schizophrenia);
- Prior history of SCI;
- Recent history (less than 1 year) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation, in the opinion of the investigator;
- Is a prisoner;
- Participation in another clinical trial within the past 30 days;
- Acquired immune deficiency syndrome (AIDS) or AIDS-related complex;
- Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated. Patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study.
Sites / Locations
- University of Alabama School of Medicine Department of Neurosurgery
- Barrow Neurological Institute St. Joseph's Hospital and Medical Center
- University of Arizona Department of Surgery Division of Neurosurgery
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
CSFD with elevation of MAP
Maintenance of MAP
Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.